Can biomarkers of coagulation, platelet activation, and inflammation predict mortality in patients with hematological malignancies?

Elmoamly, Shereef; Afif, Alaa

doi:10.1080/10245332.2017.1365458

Cited by 10 publications

(8 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…72 A meta-analysis examining the prognostic effect of circulating fibrinogen in solid tumors showed a positive correlation between pretreatment fibrinogen levels and poorer survival (hazard ratio=1.51). 73 Conflicting results came from studies on hematologic cancers, [74][75][76] but overall patients with elevated baseline plasma fibrinogen levels had a significantly poorer clinical outcome.…”

Section: Cancermentioning

confidence: 99%

Fibrin(ogen) in human disease: both friend and foe

et al. 2020

View full text Add to dashboard Cite

Ferrata Storti Foundation Fibrinogen is an abundant protein synthesized in the liver, present in human blood plasma at concentrations ranging from 1.5-4 g/L in healthy individuals with a normal half-life of 3-5 days. With fibrin, produced by thrombin-mediated cleavage, fibrinogen plays important roles in many physiological processes. Indeed, the formation of a stable blood clot, containing polymerized and cross-linked fibrin, is crucial to prevent blood loss and drive wound healing upon vascular injury. A balance between clotting, notably the conversion of fibrinogen to fibrin, and fibrinolysis, the proteolytic degradation of the fibrin mesh, is essential. Disruption of this equilibrium can cause disease in distinct manners. While some pathological conditions are the consequence of altered levels of fibrinogen, others are related to structural properties of the molecule. The source of fibrinogen expression and the localization of fibrin(ogen) protein also have clinical implications. Low levels of fibrinogen expression have been detected in extra-hepatic tissues, including carcinomas, potentially contributing to disease. Fibrin(ogen) deposits at aberrant sites including the central nervous system or kidney, can also be pathological. In this review, we discuss disorders in which fibrinogen and fibrin are implicated, highlighting mechanisms that may contribute to disease.

show abstract

Section: Cancermentioning

confidence: 99%

Fibrin(ogen) in human disease: both friend and foe

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Elmoamly S and colleagues measured inflammatory markers in a group of 171 patients with haematological malignancies. 84 The results indicated that the platelet activation marker von Willebrand Factor (vWF) was statistically related with the mortality of lymphoproliferative diseases, implying that vWF could be used as a prognostic marker. In addition, Shi L et al found that the platelet activation index is a potential marker for predicting gemcitabine/cisplatin (GP) resistance in the treatment of advanced and metastatic non-small cell lung cancer (NSCLC).…”

Section: Activated Platelets Can Participate In Tumour Formation and mentioning

confidence: 99%

Section: Osteosarcomamentioning

confidence: 99%

Platelets: The Emerging Clinical Diagnostics and Therapy Selection of Cancer Liquid Biopsies

Meng¹,

Sun²,

Yang³

et al. 2021

OTT

View full text Add to dashboard Cite

Due to the inherent molecular heterogeneity of metastatic tumours and the dynamic evolution ability of tumour genomes, tumour tissues obtained through biopsy and other methods cannot capture all of the features of tumour genomes. A new diagnostic concept called "liquid biopsy" has received widespread attention in recent years. Liquid biopsy has changed the clinical practice of oncology and is widely used to guide targeted drug utilization, monitor disease progression and track drug resistance. The latest research subject in liquid biopsy is platelets. Platelets originate from multifunctional haematopoietic stem cells in the bone marrow haematopoietic system. They are small cells from the cytoplasm of bone marrow megakaryocytes. Their main physiological functions are to participate in the processes of physiological haemostasis and coagulation. Tumour cells transfer biomolecules (such as RNA) to platelets through direct contact and release of exosomes, which changes the platelet precursor RNA. Under the stimulation of tumour cells and the tumour microenvironment, platelet precursor mRNA is spliced into mature RNA and converted into functional protein to respond to external stimuli, forming tumoureducated platelets (TEPs). The detection of TEPs in the peripheral blood of patients is expected to be used in clinical tumour diagnosis. This emerging liquid biopsy method can replace and supplement the current tumour detection methods. Further research on the role of platelets in tumour diagnosis will help provide a novel theoretical basis for clinical tumour diagnosis.

show abstract

“…Sixty patients (35%) died during the follow-up period. Some biomarkers of coagulation and inflammation showed significant associations with the mortality of patients with plasma cell dyscrasia (vWF and IL-6) and lymphoproliferative disorders (antithrombin) and could potentially be used as prognostic markers [53]. …”

Section: Discussionmentioning

confidence: 99%

Can Biomarkers of Coagulation, Platelet Activation, and Inflammation Predict Venous Thromboembolism in Patients with Haematological Malignancies?

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background: The incidence of venous thromboembolism (VTE) in haematological malignancies varies according to the type and grade of the disease and clinical variables, and there is a need to develop a tool to predict the occurrence of VTE in cancer patients at diagnosis to tailor prophylactic anticoagulation use during treatment. Objective: To study the incidence of VTE in haematological malignancies and clarify whether vascular and inflammatory biomarkers could be used as predictors of VTE in those patients. Methods: This was a prospective observational cohort study. Hypercoagulability and inflammatory biomarkers were assayed in a group of 171 patients with haematological malignancies at diagnosis. These markers included (1) coagulation and fibrinolysis activation markers (D-dimer, fibrinogen, antithrombin, plasminogen activator inhibitor 1), (2) endothelial and platelet activation markers (von Willebrand factor and soluble P-selectin), and (3) inflammatory markers (tumour necrosis factor αand interleukin 6). The end point was mortality or symptomatic VTE. Results/Conclusion: The incidence of symptomatic VTE was 7%. None of the tested biomarkers showed statistical significance as predictors for the occurrence of VTE in haematological malignancies. However, there were statistically significant associations between the occurrence of VTE and central venous access device insertion, the prothrombin time, and the erythrocyte sedimentation rate. An ESR above 106.5 mm/h is associated with increased VTE occurrence.

show abstract

Can biomarkers of coagulation, platelet activation, and inflammation predict mortality in patients with hematological malignancies?

Abstract: Some biomarkers of coagulation and inflammation showed statistically significant associations with plasma cell dyscrasias mortality (vWF and IL-6) and lymphoproliferative disorders mortality (Antithrombin) and potentially could be used as prognostic markers.

Cited by 10 publications

References 38 publications

Fibrin(ogen) in human disease: both friend and foe

Fibrin(ogen) in human disease: both friend and foe

Platelets: The Emerging Clinical Diagnostics and Therapy Selection of Cancer Liquid Biopsies

Can Biomarkers of Coagulation, Platelet Activation, and Inflammation Predict Venous Thromboembolism in Patients with Haematological Malignancies?

Contact Info

Product

Resources

About